<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Drug Manufacturers &#8211; Other</title>
	<atom:link href="http://www.stockbloghub.com/category/drugmanufacturersother/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 16 May 2012 17:53:30 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(ALXN) Alexion Pharmaceuticals &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2012/04/19/alxn-alexion-pharmaceuticals-bull-of-the-day-2/99142</link>
		<comments>http://www.stockbloghub.com/2012/04/19/alxn-alexion-pharmaceuticals-bull-of-the-day-2/99142#comments</comments>
		<pubDate>Thu, 19 Apr 2012 18:28:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alexion Pharmaceuticals Inc]]></category>
		<category><![CDATA[ALXN]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=99142</guid>
		<description><![CDATA[We are upgrading Alexion Pharmaceuticals (ALXN) to Outperform from Neutral on valuation grounds; we believe that there is significant upside scope from current levels. Alexion performed very well in the final quarter of 2011, beating the Zacks Consensus Estimate by $0.07 thanks to strong Soliris sales. We are also impressed by the label expansion of Soliris in the US and EU for the aHUS indication, which has boosted the sales potential of the drug. We expect Soliris to continue performing well in 2012. Consequently, we have increased our revenue estimate for 2012 and expect Soliris sales to exceed $1 billion in 2012. Management, too, gave a bright outlook for 2012. Our long-term recommendation is in line with the Zacks #1 Rank (Strong Buy rating) carried by the stock in the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/19/alxn-alexion-pharmaceuticals-bull-of-the-day-2/99142/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TEVA) Teva Pharmaceutical Industries Active on the Generics Front</title>
		<link>http://www.stockbloghub.com/2012/04/09/teva-teva-pharmaceutical-industries-active-on-the-generics-front/97937</link>
		<comments>http://www.stockbloghub.com/2012/04/09/teva-teva-pharmaceutical-industries-active-on-the-generics-front/97937#comments</comments>
		<pubDate>Mon, 09 Apr 2012 18:03:27 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=97937</guid>
		<description><![CDATA[Teva Pharmaceutical Industries Ltd. (TEVA) has been pretty active on the generic product launch front with the company launching several generic products in the last few weeks. Among recently launched generic products are Teva’s generic versions of Sanofi’s (SNY) high blood pressure drugs, Avapro and Avalide, AstraZeneca’s (AZN) schizophrenia treatment, Seroquel, and Forest Laboratories’ (FRX) Lexapro. While Teva will enjoy a 180-day period of marketing exclusivity where the generic launches of Avapro, Avalide and Lexapro are concerned, we note that other generic players like Dr. Reddy’s Laboratories (RDY) and Mylan (MYL) have also launched their generic versions of Seroquel. As per IMS data, annual US sales of Avapro, Avalide, Seroquel, and Lexapro were $464 million, $124 million, $4.6 billion and $2.9 billion, respectively. Teva also launched its authorized generic of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/09/teva-teva-pharmaceutical-industries-active-on-the-generics-front/97937/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(FRX) Forest Laboratories and Janssen Pharmaceutica Sue Generic Players</title>
		<link>http://www.stockbloghub.com/2012/03/19/frx-forest-laboratories-and-janssen-pharmaceutica-sue-generic-players/95647</link>
		<comments>http://www.stockbloghub.com/2012/03/19/frx-forest-laboratories-and-janssen-pharmaceutica-sue-generic-players/95647#comments</comments>
		<pubDate>Tue, 20 Mar 2012 02:16:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=95647</guid>
		<description><![CDATA[Forest Laboratories, Inc. (FRX) and Janssen Pharmaceutica NV, a Johnson &#38; Johnson (JNJ) company, recently filed a joint lawsuit against several generic companies that are looking to launch their generic versions of Bystolic (nebivolol). The patent infringement lawsuit has been filed in the US District Court for the District of Delaware for infringement of US Patent No. 6,545,040. The lawsuit has been filed against companies like Amerigen Pharmaceuticals, Inc., Glenmark Generics, Inc., Hetero USA Inc., Torrent Pharmaceuticals Ltd., Watson Laboratories, Inc. (WPI). Another patent infringement lawsuit has been filed by Forest Labs and Janssen in the US District Court for the Northern District of Illinois against Alkem Laboratories Limited and Indchemie Health Specialties Pvt. Ltd. This lawsuit is also related to the infringement of the ‘040 patent. With the lawsuits ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/03/19/frx-forest-laboratories-and-janssen-pharmaceutica-sue-generic-players/95647/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(FRX) Forest Laboratories Earns Positive News on Pipeline</title>
		<link>http://www.stockbloghub.com/2012/03/06/frx-forest-laboratories-earns-positive-news-on-pipeline/94441</link>
		<comments>http://www.stockbloghub.com/2012/03/06/frx-forest-laboratories-earns-positive-news-on-pipeline/94441#comments</comments>
		<pubDate>Tue, 06 Mar 2012 21:31:50 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MDD]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[SPDR S&P International Mid Cap]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=94441</guid>
		<description><![CDATA[Forest Laboratories, Inc. (FRX) recently reported back-to-back positive news on the pipeline front. The company and partner Gedeon Richter Plc. announced that their late-stage anti-psychotic candidate, cariprazine, met its primary endpoint in two phase III studies. The studies were conducted to evaluate cariprazine for the treatment of acute exacerbation of schizophrenia. Results showed that patients in the cariprazine arm achieved a significant improvement in symptom compared to patients in the placebo arm. Statistically significant separation from placebo was observed in all doses from week 2 and at each subsequent time point. Forest Labs and Gedeon said that the higher dose showed separation as early as week 1 of treatment.  The results were similar to data presented earlier from a phase IIb fixed-dose placebo-controlled study. Cariprazine is one of the candidates ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/03/06/frx-forest-laboratories-earns-positive-news-on-pipeline/94441/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SHPGY) Shire and Sangamo BioSciences Cut a Deal</title>
		<link>http://www.stockbloghub.com/2012/02/14/shpgy-shire-and-sangamo-biosciences-cut-a-deal/91440</link>
		<comments>http://www.stockbloghub.com/2012/02/14/shpgy-shire-and-sangamo-biosciences-cut-a-deal/91440#comments</comments>
		<pubDate>Tue, 14 Feb 2012 15:22:50 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Impax Laboratories Inc]]></category>
		<category><![CDATA[IPXL]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Sangamo Biosciences Inc]]></category>
		<category><![CDATA[SGMO]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=91440</guid>
		<description><![CDATA[Shire plc (SHPGY) and Sangamo BioSciences, Inc. (SGMO) recently entered into a collaboration and license agreement for the development of products for hemophilia and other monogenic diseases. These products will be developed using Sangamo’s zinc finger DNA-binding protein (”ZFP”) technology. Terms of the Deal Shire will make an upfront payment of $13 million to Sangamo. Sangamo will also be eligible to receive milestone payments of up to $213.5 million based on the achievement of research, regulatory, development and commercial targets. Shire will pay Sangamo tiered double-digit royalties on product sales. As per the agreement, Shire will get exclusive global rights to ZFP therapeutics designed to target 4 genes for investigating curative therapies for hemophilia A and B. Shire also gets the right to designate 3 additional gene targets. While Sangamo ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/02/14/shpgy-shire-and-sangamo-biosciences-cut-a-deal/91440/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(FRX) Forest Laboratories Learns of Positive Results on Gedeon Drug</title>
		<link>http://www.stockbloghub.com/2012/02/13/frx-forest-laboratories-learns-of-positive-results-on-gedeon-drug/91536</link>
		<comments>http://www.stockbloghub.com/2012/02/13/frx-forest-laboratories-learns-of-positive-results-on-gedeon-drug/91536#comments</comments>
		<pubDate>Tue, 14 Feb 2012 04:54:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MDD]]></category>
		<category><![CDATA[SPDR S&P International Mid Cap]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=91536</guid>
		<description><![CDATA[Forest Laboratories, Inc. (FRX) and partner Gedeon Richter recently presented positive top-line results on their antipsychotic candidate, cariprazine (RGH-188). Preliminary top-line results were presented from a phase III study that was conducted in patients with acute mania associated with bipolar I disorder. Results from the five-week multi-center, double-blind, placebo-controlled, parallel-group study showed that patients in the cariprazine arm experienced significant symptom improvement compared to patients in the placebo arm. The improvement was observed as early as the fifth day of treatment and at each subsequent time point studied. Cariprazine, a novel, orally active D2/D3 antagonist, was generally well tolerated. However, discontinuations due to adverse events were higher in the cariprazine arms compared to placebo. Forest Labs intends to analyze the data further. Results from this study were similar to those ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/02/13/frx-forest-laboratories-learns-of-positive-results-on-gedeon-drug/91536/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ARQL) Company News for January 18, 2012 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2012/01/18/arql-company-news-for-january-18-2012-corporate-summary/90416</link>
		<comments>http://www.stockbloghub.com/2012/01/18/arql-company-news-for-january-18-2012-corporate-summary/90416#comments</comments>
		<pubDate>Wed, 18 Jan 2012 20:42:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ARQL]]></category>
		<category><![CDATA[ArQule Inc]]></category>
		<category><![CDATA[Blackbaud Inc]]></category>
		<category><![CDATA[BLKB]]></category>
		<category><![CDATA[ISTA]]></category>
		<category><![CDATA[ISTA Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Valeant Pharmaceuticals International]]></category>
		<category><![CDATA[Venoco Inc]]></category>
		<category><![CDATA[VQ]]></category>
		<category><![CDATA[VRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=90416</guid>
		<description><![CDATA[•    Bio technology company ArQule Inc.’s (NASDAQ:ARQL) share prices gained 11.91% to close at $6.67 after the company&#8217;s experimental treatment for liver cancer reported a positive outcome in its Phase II trial •    Share prices of discount carrier Sprint Airlines Inc. (NASDAQ:SAVE) declined 5.53% after the company announced plans to sell 11 million shares in a secondary offering •    Global provider of software Blackbaud Inc. (NASDAQ:BLKB) will buy fund raising software maker Convio Inc. (NASDAQ:CNVO) for $16 per share. Following the news, shares of Convio rocketed up 48% to close at $15.89 a share •    ISTA Pharmaceuticals Inc.’s shares (NASDAQ:ISTA) gained 13.07% after Valeant Pharmaceuticals International Inc. (NYSE:VRX) increased its hostile-takeover bid for ISTA to $7.50 a share •    Shares of natural gas firm Venoco Inc. (NYSE:VQ) surged 29.91% to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/18/arql-company-news-for-january-18-2012-corporate-summary/90416/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TEVA) Teva Pharmaceutical Industries Provides In-Line 2012 Outlook</title>
		<link>http://www.stockbloghub.com/2011/12/27/teva-teva-pharmaceutical-industries-provides-in-line-2012-outlook/89233</link>
		<comments>http://www.stockbloghub.com/2011/12/27/teva-teva-pharmaceutical-industries-provides-in-line-2012-outlook/89233#comments</comments>
		<pubDate>Wed, 28 Dec 2011 03:58:13 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[PG]]></category>
		<category><![CDATA[Procter & Gamble Company]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=89233</guid>
		<description><![CDATA[Teva Pharmaceutical Industries Ltd. (TEVA) recently provided guidance for 2012. The company expects to earn $5.48 and $5.68 per share on total net sales of about $22 billion. Guidance was generally in line with expectations. While the Zacks Consensus Earnings Estimate, prior to the release of guidance, was $5.62, the Zacks Consensus Revenue Estimate was about $21.8 billion. The Cephalon acquisition is expected to boost 2012 earnings by 20-25 cents. Teva expects to generate $11 billion sales in the US with the EU and Rest of the World (RoW) generating sales of $6.6 billion and $4.4 billion, respectively. The major chunk of revenues ($11.8 billion) will be provided by the generics business. US Generics Biz to Rebound Teva’s US generics business, which has been performing below expectations over the past ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/27/teva-teva-pharmaceutical-industries-provides-in-line-2012-outlook/89233/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ISIS) Isis Pharmaceuticals Analyst Downgrades Shares to Neutral</title>
		<link>http://www.stockbloghub.com/2011/11/30/isis-isis-pharmaceuticals-analyst-downgrades-shares-to-neutral/87746</link>
		<comments>http://www.stockbloghub.com/2011/11/30/isis-isis-pharmaceuticals-analyst-downgrades-shares-to-neutral/87746#comments</comments>
		<pubDate>Wed, 30 Nov 2011 18:51:47 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87746</guid>
		<description><![CDATA[We recently downgraded Isis Pharmaceuticals (ISIS) to Neutral from an Outperform recommendation. Isis Pharma is a drug discovery and development company that focuses on the development of products using ribonucleic acid (RNA)-based technologies, such as antisense. The company discovers new drugs and out-licenses them to partners for license fees, milestone payments, and royalties. Isis Pharma’s lead pipeline candidate, Kynamro (mipomersen), is being developed for the treatment of familial hypercholesterolemia (FH). Isis Pharma has a collaboration agreement with Genzyme, a subsidiary of Sanofi-Aventis (SNY) for Kynamro. While the companies filed for EU approval of Kynamro in July, the US filing is scheduled to take place later this month. Acceptance of the US filing will trigger a $25 million milestone payment from Sanofi, most likely in early 2012. Isis Pharma and Sanofi ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/30/isis-isis-pharmaceuticals-analyst-downgrades-shares-to-neutral/87746/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VRTX) Vertex Pharmaceuticals Riding High on Incivek Sales</title>
		<link>http://www.stockbloghub.com/2011/11/02/vrtx-vertex-pharmaceuticals-riding-high-on-incivek-sales/86343</link>
		<comments>http://www.stockbloghub.com/2011/11/02/vrtx-vertex-pharmaceuticals-riding-high-on-incivek-sales/86343#comments</comments>
		<pubDate>Wed, 02 Nov 2011 17:08:20 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CF]]></category>
		<category><![CDATA[CF Industries Holdings Inc.]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MAA]]></category>
		<category><![CDATA[Mid-America Apartment Communities Inc]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=86343</guid>
		<description><![CDATA[Vertex Pharmaceuticals Inc. (VRTX) posted robust third quarter 2011 earnings (including stock-based compensation expense) of 56 cents per share, substantially above the Zacks Consensus Estimate of 19 cents and the year-ago loss of 99 cents. Increased revenues from the sale of hepatitis C virus (HCV) treatment, Incivek (telaprevir) helped record positive earnings. Revenues Riding on the strong sales of Incivek, which was launched in the second quarter of 2011, Vertex Pharma reported total revenue of $659.2 million, almost double the Zacks Consensus Estimate of $342 million and significantly above the year-ago figure of $23.8 million. Vertex Pharma’s third quarter revenues consisted of revenue earned from the sale of Incivek ($419.6 million), royalty revenue (up 4.5% to $8.5 million) and collaborative revenue (up 137.9% to $231.1 million). Collaborative revenue for the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/02/vrtx-vertex-pharmaceuticals-riding-high-on-incivek-sales/86343/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(RDY) Dr. Reddy’s Laboratories Continues to Grow</title>
		<link>http://www.stockbloghub.com/2011/10/28/rdy-dr-reddy%e2%80%99s-laboratories-continues-to-grow/86019</link>
		<comments>http://www.stockbloghub.com/2011/10/28/rdy-dr-reddy%e2%80%99s-laboratories-continues-to-grow/86019#comments</comments>
		<pubDate>Fri, 28 Oct 2011 15:52:24 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ADS]]></category>
		<category><![CDATA[Alliance Data Systems Corporation]]></category>
		<category><![CDATA[DMF]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[Dreyfus Municipal Income Inc]]></category>
		<category><![CDATA[RDY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=86019</guid>
		<description><![CDATA[Dr. Reddy’s Laboratories (RDY) reported second quarter fiscal 2012 earnings per American Depositary Share (ADS) of 40 cents, significantly above the year-ago earnings of 30 cents per ADS. Higher revenues helped boost earnings. Quarter at a Glance The company reported revenues of $462 million during the fiscal year, reflecting a year-over-year increase of 22%. Dr. Reddy’s reports revenues under two segments – Global Generics and Pharmaceutical Services &#38; Active Ingredients (PSAI). While, revenues at the Global Generics segment increased 18% to $329 million, PSAI revenues shot up 28% to $121 million during the quarter. While generics revenues increased 45% in North America, 23% in Russia and other CIS (Commonwealth of Independent States) markets, and 9% in India, they deteriorated 10% in Europe. In the European market, Germany was worst hit ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/10/28/rdy-dr-reddy%e2%80%99s-laboratories-continues-to-grow/86019/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALXN) Alexion Pharmaceuticals &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2011/10/27/alxn-alexion-pharmaceuticals-bull-of-the-day/86000</link>
		<comments>http://www.stockbloghub.com/2011/10/27/alxn-alexion-pharmaceuticals-bull-of-the-day/86000#comments</comments>
		<pubDate>Thu, 27 Oct 2011 17:25:14 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alexion Pharmaceuticals Inc]]></category>
		<category><![CDATA[ALXN]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=86000</guid>
		<description><![CDATA[Alexion Pharmaceuticals&#8217; (ALXN) third quarter 2011 adjusted earnings of $0.32 per share breezed past the Zacks Consensus Estimate by $0.09 and the year-ago adjusted earnings by $0.11. Results were driven by increased revenues thanks to a strong performance by Soliris, Alexion&#8217;s sole marketed product. Following strong third quarter results, Alexion upped its guidance for 2011. Our estimate is within the revised guidance range provided by the company. We are also impressed by the successful label expansion of Soliris into the aHUS indication in the US and the positive recommendation in the EU. The string of good news has boosted the stock. We expect the stock to continue performing well and believe that the current price represents an attractive entry point for long-term investors. Our target price is $82.00. ALEXION PHARMA ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/10/27/alxn-alexion-pharmaceuticals-bull-of-the-day/86000/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALXA) Company News for October 5, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/10/06/alxa-company-news-for-october-5-2011-corporate-summary/84644</link>
		<comments>http://www.stockbloghub.com/2011/10/06/alxa-company-news-for-october-5-2011-corporate-summary/84644#comments</comments>
		<pubDate>Thu, 06 Oct 2011 15:16:49 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alexandria Real Estate Equities Inc]]></category>
		<category><![CDATA[Alexion Pharmaceuticals Inc]]></category>
		<category><![CDATA[Alexza Pharmaceuticals Inc]]></category>
		<category><![CDATA[ALXA]]></category>
		<category><![CDATA[ALXN]]></category>
		<category><![CDATA[ARE]]></category>
		<category><![CDATA[General Maritime Corporation]]></category>
		<category><![CDATA[GMR]]></category>
		<category><![CDATA[NRG]]></category>
		<category><![CDATA[NRG Energy Inc.]]></category>
		<category><![CDATA[Red Hat Inc.]]></category>
		<category><![CDATA[RHT]]></category>
		<category><![CDATA[S]]></category>
		<category><![CDATA[Sprint Nextel Corporation]]></category>
		<category><![CDATA[Transcept Pharmaceuticals Inc]]></category>
		<category><![CDATA[TSPT]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=84644</guid>
		<description><![CDATA[•    Drug developer Transcept Pharmaceuticals Inc.’s (NASDAQ:TSPT) shares increased 33.77% to close at $8.08 after the company&#8217;s experimental sleep treatment got approved from the regulators •    Share prices of General Maritime Corp. (NYSE:GMR) declined 7.35%  after the company reported its plans for a possible restructuring •    Shares of power company NRG Energy Inc. (NYSE:NRG) shed 1.81% to close at $19.57 after the company lowered down its earnings outlook for 2011 •    Software company Red Hat Inc. (NYSE:RHT) announced that it would acquire software developer Gluster Inc. in a deal worth $136 million •    Share prices of phone carrier Sprint-Nextel (NYSE:S) advanced 4.76% on news that the company will offer the iPhone 4S on its inaugural day on 14th October •    Analysts at Goldman Sachs upgraded shares of Kinder Morgan (NYSE:KMI) ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/10/06/alxa-company-news-for-october-5-2011-corporate-summary/84644/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OREX) Orexigen Therapeutics Lifeline for Contrave</title>
		<link>http://www.stockbloghub.com/2011/09/24/orex-orexigen-therapeutics-lifeline-for-contrave/83937</link>
		<comments>http://www.stockbloghub.com/2011/09/24/orex-orexigen-therapeutics-lifeline-for-contrave/83937#comments</comments>
		<pubDate>Sat, 24 Sep 2011 19:00:08 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Arena Pharmaceuticals Inc.]]></category>
		<category><![CDATA[ARNA]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[OREX]]></category>
		<category><![CDATA[Orexigen Therapeutics Inc.]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83937</guid>
		<description><![CDATA[Orexigen Therapeutics, Inc.&#8216;s (OREX) shares climbed significantly following a meeting with the US Food and Drug Administration&#8217;s (FDA) office of new drugs (OND) regarding the development path for its obesity candidate Contrave. Following the OND’s decision, Orexigen decided to resume the development of Contrave. Orexigen is looking to gain approval for Contrave for the treatment of obesity, including weight loss and maintenance of weight loss. The company has a collaboration agreement with Takeda for the development and commercialization of Contrave in the US, Canada and Mexico. Story so far…. In January 2011, Orexigen received a complete response letter (CRL) from the FDA for Contrave. The FDA  expressed concerns regarding the long-term cardiovascular safety profile of Contrave and asked Orexigen to conduct an additional study. The FDA requested a randomized, double-blind, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/24/orex-orexigen-therapeutics-lifeline-for-contrave/83937/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVO) Novo Nordisk Data Presented at European Association for the Study of Diabetes</title>
		<link>http://www.stockbloghub.com/2011/09/19/nvo-novo-nordisk-data-presented-at-european-association-for-the-study-of-diabetes/83265</link>
		<comments>http://www.stockbloghub.com/2011/09/19/nvo-novo-nordisk-data-presented-at-european-association-for-the-study-of-diabetes/83265#comments</comments>
		<pubDate>Mon, 19 Sep 2011 20:38:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83265</guid>
		<description><![CDATA[Novo Nordisk (NVO) recently presented data from two trials of its lead diabetes drug, Victoza, at the European Association for the Study of Diabetes (EASD). The first trial showed that using Victoza at an early stage in diabetes treatment of patients with type II diabetes, who had not received any treatment before or previously received only one oral anti-diabetic drug (OAD), led to greater improvements in glycaemic control than those who had been dosed two or more OAD’s. The second trial showed that when type II diabetes patients switched from oral treatment with Merck’s (MRK) Januvia to injectable Victoza (once daily) experienced increased treatment satisfaction as well as significant reductions in blood glucose and body weight. We remind investors that in June this year, Novo Nordisk had presented data from ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/19/nvo-novo-nordisk-data-presented-at-european-association-for-the-study-of-diabetes/83265/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VRTX) Vertex Pharmaceuticals Reports Positive Data</title>
		<link>http://www.stockbloghub.com/2011/09/12/vrtx-vertex-pharmaceuticals-reports-positive-data/82979</link>
		<comments>http://www.stockbloghub.com/2011/09/12/vrtx-vertex-pharmaceuticals-reports-positive-data/82979#comments</comments>
		<pubDate>Mon, 12 Sep 2011 17:19:46 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BID]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MAA]]></category>
		<category><![CDATA[Mid-America Apartment Communities Inc]]></category>
		<category><![CDATA[RA]]></category>
		<category><![CDATA[Railamerica Inc]]></category>
		<category><![CDATA[Sotheby's]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=82979</guid>
		<description><![CDATA[Vertex Pharmaceuticals Inc. (VRTX) reported positive data from a mid-stage trial on VX-509, which is being studied for the treatment of moderate to severe rheumatoid arthritis (RA). The 12-week study, which evaluated four doses of the candidate, met both the primary endpoints. Data from the two highest dose (100 mg and 150 mg) treatment arms demonstrated significant improvement in the proportion of people who achieved at least a 20% improvement in the signs and symptoms of RA (ACR20), and a statistically significant improvement from baseline in Disease Activity Score 28 (DAS28), compared to placebo. The study also met the secondary endpoints (ACR50 and ACR70) of achieving statistically significant responses compared to placebo. On the basis of the data from the phase IIa study, Vertex Pharma plans to initiate a six-month ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/12/vrtx-vertex-pharmaceuticals-reports-positive-data/82979/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SCR) Simcere Drug Cleared in China</title>
		<link>http://www.stockbloghub.com/2011/09/01/scr-simcere-drug-cleared-in-china/82262</link>
		<comments>http://www.stockbloghub.com/2011/09/01/scr-simcere-drug-cleared-in-china/82262#comments</comments>
		<pubDate>Thu, 01 Sep 2011 17:26:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RA]]></category>
		<category><![CDATA[Railamerica Inc]]></category>
		<category><![CDATA[SCR]]></category>
		<category><![CDATA[Simcere Pharmaceutical Group.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=82262</guid>
		<description><![CDATA[Recently, the State Food and Drug Administration (SFDA) of China delivered a boost to Simcere Pharmaceutical Group (SCR) by clearing its drug Iremod, for treating patients suffering from active rheumatoid arthritis (RA). Iremod, developed solely by Simcere, will be the first Iguratimod drug to hit the global market and will be used mainly to treat patients suffering from active RA. Iguratimod refers to a new disease-modifying, anti-rheumatoid therapy and belongs to the category of Disease Modifying Anti-rheumatic Drugs (DMARDs). The approval of Iremod by the Chinese regulatory authorities will not only boost Simcere’s top line but also widen the treatment options for patients suffering from the dreaded disease, whose incidence is on the rise. Iremod will operate in a highly lucrative market and will compete with players like Bristol-Myers (BMY), ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/01/scr-simcere-drug-cleared-in-china/82262/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TEVA) Teva Pharmaceutical Industries Earns Favorable Court Ruling</title>
		<link>http://www.stockbloghub.com/2011/09/01/teva-teva-pharmaceutical-industries-earns-favorable-court-ruling/82359</link>
		<comments>http://www.stockbloghub.com/2011/09/01/teva-teva-pharmaceutical-industries-earns-favorable-court-ruling/82359#comments</comments>
		<pubDate>Thu, 01 Sep 2011 16:57:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Canadian Pacific Railway Limited]]></category>
		<category><![CDATA[CP]]></category>
		<category><![CDATA[MNTA]]></category>
		<category><![CDATA[Momenta Pharmaceuticals Inc]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=82359</guid>
		<description><![CDATA[Teva Pharmaceutical Industries Ltd. (TEVA) recently received a boost with the US District Court for the Southern District of New York issuing a favorable ruling related to the company’s patent infringement lawsuit against Novartis AG (NVS)/Momenta Pharmaceuticals, Inc. (MNTA) and Mylan Inc. (MYL)/Natco Pharma Ltd. The lawsuit is regarding the company’s lead drug Copaxone, marketed for the treatment of multiple sclerosis (MS). The Court adopted all relevant claim construction interpretations of Teva and rejected all the claim construction interpretations put forth by Novartis/Momenta and Mylan/Natco. Moreover, the Court denied Mylan&#8217;s motion for summary judgment that the disputed patents are invalid for indefiniteness. We note that Teva’s patent for Copaxone is set to expire in 2014. The company has filed a Citizen Petition (CP) with the US Food and Drug Administration ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/01/teva-teva-pharmaceutical-industries-earns-favorable-court-ruling/82359/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SCR) Simcere Pharmaceutical Group Beats on Bottom Line</title>
		<link>http://www.stockbloghub.com/2011/08/16/scr-simcere-pharmaceutical-group-beats-on-bottom-line/81398</link>
		<comments>http://www.stockbloghub.com/2011/08/16/scr-simcere-pharmaceutical-group-beats-on-bottom-line/81398#comments</comments>
		<pubDate>Tue, 16 Aug 2011 17:01:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ADS]]></category>
		<category><![CDATA[Alliance Data Systems Corporation]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[SCR]]></category>
		<category><![CDATA[Simcere Pharmaceutical Group.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=81398</guid>
		<description><![CDATA[Simcere Pharmaceutical Group’s (SCR) second quarter 2011 earnings of 21 cents per American Depositary Share (ADS) surpassed the Zacks Consensus Estimate of 13 cents and the year-ago earnings of 10 cents. Increased revenues and lower share count helped boost earnings. Revenues Revenues at Simcere Pharma came in at $84.4 million in the second quarter, up 0.3% year over year in local currency. Revenues however fell short of the Zacks Consensus Estimate of $89 million. Higher sales of drugs, Endu (up 30.3% in local currency to $10.8 million), Sinofuan (up 25.8% in local currency to $8.2 million) and edaravone injection products (up 12.7% in local currency to $33.7 million) helped boost revenues. Other Details Gross margin declined to 84.9% during the quarter, compared with 86.8% in the prior-year quarter. A rise ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/16/scr-simcere-pharmaceutical-group-beats-on-bottom-line/81398/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VRX) Valeant Pharmaceuticals International Beats Expectations &#8211; Ups View</title>
		<link>http://www.stockbloghub.com/2011/08/08/vrx-valeant-pharmaceuticals-international-beats-expectations-ups-view/80862</link>
		<comments>http://www.stockbloghub.com/2011/08/08/vrx-valeant-pharmaceuticals-international-beats-expectations-ups-view/80862#comments</comments>
		<pubDate>Mon, 08 Aug 2011 17:31:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Cogdell Spencer Inc.]]></category>
		<category><![CDATA[CSA]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[Valeant Pharmaceuticals International]]></category>
		<category><![CDATA[VRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80862</guid>
		<description><![CDATA[Valeant Pharmaceuticals International’s (VRX) second quarter 2011 earnings of 68 cents per share (excluding special items but including stock based compensation expense) beat the Zacks Consensus Estimate by 3 cents and the year-ago earnings by 8 cents per share. Bottom-line growth was driven by improved revenues. Adjusted diluted earnings, however, included an extraordinary gain of 6 cents from the sale of investment in Cephalon Inc. (CEPH). Revenues for the quarter were $609.4 million, marginally above the Zacks Consensus Estimate of $609 million and way ahead of the prior-year figure of $238.8 million. However, revenue included a one-time milestone payment of $40 million received from GlaxoSmithkline (GSK) related to the European launch of Trobalt (known as Potiga in the US). The improvement in revenues was primarily due to the September 2010 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/08/vrx-valeant-pharmaceuticals-international-beats-expectations-ups-view/80862/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AGN) Company News for August 5, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/08/05/agn-company-news-for-august-5-2011-corporate-summary/80747</link>
		<comments>http://www.stockbloghub.com/2011/08/05/agn-company-news-for-august-5-2011-corporate-summary/80747#comments</comments>
		<pubDate>Fri, 05 Aug 2011 16:18:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[BX]]></category>
		<category><![CDATA[Clorox Corporation]]></category>
		<category><![CDATA[CLX]]></category>
		<category><![CDATA[General Motors]]></category>
		<category><![CDATA[GM]]></category>
		<category><![CDATA[KFT]]></category>
		<category><![CDATA[Kraft Foods Inc.]]></category>
		<category><![CDATA[NRG]]></category>
		<category><![CDATA[NRG Energy Inc.]]></category>
		<category><![CDATA[Piper Jaffray Companies]]></category>
		<category><![CDATA[PJC]]></category>
		<category><![CDATA[The Blackstone Group]]></category>
		<category><![CDATA[Web.com Group Inc]]></category>
		<category><![CDATA[Wells Fargo & Company]]></category>
		<category><![CDATA[WFC]]></category>
		<category><![CDATA[WWWW]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80747</guid>
		<description><![CDATA[•    NRG Energy (NYSE:NRG) posted Q2 EPS of $2.53, clearly beating the Zacks Consensus Estimate of $0.38 per share. Revenues for the quarter rose 6.8% year-over-year to $2.28 billion, which came in lower than the Zacks Consensus Estimate of $2.7 billion •    Shares of Kraft Foods (NYSE:KFT) opened higher after the company announced plans to split the company into two separate public companies. However, shares of the company lost ground and closed 1.52% lower •    General Motors (NYSE:GM) reported adjusted Q2 EPS of $1.54, beating the Zacks Consensus Estimate of $1.21 per share. Revenues for the quarter rose 18.7% year-over-year to $39.40 billion, exceeding the Zacks Consensus Estimate of $36.61 billion •    Health-care info-tech provider Emdeon Inc (NYSE:EM) is to be acquired by private equity firm Blackstone Group (NYSE:BX). Following ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/05/agn-company-news-for-august-5-2011-corporate-summary/80747/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AGN) Allergan Beats &#8211; Revisits Guidance</title>
		<link>http://www.stockbloghub.com/2011/08/03/agn-allergan-beats-revisits-guidance/80566</link>
		<comments>http://www.stockbloghub.com/2011/08/03/agn-allergan-beats-revisits-guidance/80566#comments</comments>
		<pubDate>Wed, 03 Aug 2011 23:12:11 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MAP Pharmaceuticals Inc]]></category>
		<category><![CDATA[MAPP]]></category>
		<category><![CDATA[Medicis Pharmaceutical Corporation]]></category>
		<category><![CDATA[MRX]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80566</guid>
		<description><![CDATA[Allergan, Inc.’s (AGN) second quarter 2011 earnings of 96 cents per share inched ahead of the Zacks Consensus Estimate by a penny and surpassed the company’s guidance range of 93 – 95 cents. Earnings increased 12.9% from the year-ago quarter. Revenues Revenues increased 13.6% to $1,417.2 million, easily exceeding the Zacks Consensus Estimate of $1,339 million. Specialty pharmaceuticals sales increased 14.0% to $1,155.3 million, with eye care pharmaceutical sales increasing 13.8%. Strong performance of products like Lumigan and Restasis helped drive eye-care sales. Alphagan and Combigan franchise sales went up 4.1% to $108.5 million in the reported quarter. New product Latisse contributed $21.9 million to the second quarter sales. Botox sales increased 16.1% year on year to $418.4 million. Going forward, Allergan is looking to boost Botox sales by gaining ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/03/agn-allergan-beats-revisits-guidance/80566/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VRTX) Vertex Pharmaceuticals Loss Reduced by Incivek</title>
		<link>http://www.stockbloghub.com/2011/08/01/vrtx-vertex-pharmaceuticals-loss-reduced-by-incivek/80310</link>
		<comments>http://www.stockbloghub.com/2011/08/01/vrtx-vertex-pharmaceuticals-loss-reduced-by-incivek/80310#comments</comments>
		<pubDate>Mon, 01 Aug 2011 16:40:42 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CF]]></category>
		<category><![CDATA[CF Industries Holdings Inc.]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MAA]]></category>
		<category><![CDATA[Mid-America Apartment Communities Inc]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80310</guid>
		<description><![CDATA[Vertex Pharmaceuticals Inc. (VRTX) posted second quarter 2011 loss (including stock-based compensation expense) of 82 cents per share, narrower than the Zacks Consensus Estimate of 93 cents and the year-ago loss of 83 cents. Increased revenues from the sale of hepatitis C virus (HCV) candidate, Incivek (telaprevir) helped reduce the loss. Revenues Riding on the strong sales of Incivek, which was launched during the quarter, total revenue soared 262% to $114.4 million, surpassing the Zacks Consensus Estimate of $54 million. Vertex Pharma’s first quarter revenues consisted of revenue earned from the sale of Incivek ($74.5 million), royalty revenue (up 37.8% to $10.0 million) and collaborative revenue (up 22.7% to $30.0 million). The company receives royalty from GlaxoSmithKline plc (GSK) on sales of Lexiva, a HIV protease inhibitor. Collaborative revenue consists ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/01/vrtx-vertex-pharmaceuticals-loss-reduced-by-incivek/80310/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(RDEA) Ardea Biosciences &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2011/07/15/rdea-ardea-biosciences-bull-of-the-day/79145</link>
		<comments>http://www.stockbloghub.com/2011/07/15/rdea-ardea-biosciences-bull-of-the-day/79145#comments</comments>
		<pubDate>Fri, 15 Jul 2011 14:09:45 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Ardea Biosciences Inc.]]></category>
		<category><![CDATA[RDEA]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=79145</guid>
		<description><![CDATA[We are upgrading Ardea Biosciences Inc (RDEA) to Outperform from Neutral due to the promise shown by its lead pipeline candidate lesinurad, which is being developed for treating hyperuricemia and gout. Lesinurad, which has performed well in clinical studies, will target a market with huge unmet need on approval. The current therapies have limited efficacy with many gout patients failing to respond favorably to these therapies. This should provide lesinurad with the opportunity to take away share from currently approved therapies. The impressive balance sheet at Ardea, which has been strengthened by the signing of the lucrative agreement with Bayer, is another positive for the company. We believe that the current price represents an attractive entry point for long-term investors. ARDEA BIOSCIENC (RDEA): Free Stock Analysis Report Zacks Investment Research]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/15/rdea-ardea-biosciences-bull-of-the-day/79145/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(RDY) Dr. Reddy&#8217;s Laboratories Earns FDA Approval for Generic</title>
		<link>http://www.stockbloghub.com/2011/07/14/rdy-dr-reddys-laboratories-earns-fda-approval-for-generic/79064</link>
		<comments>http://www.stockbloghub.com/2011/07/14/rdy-dr-reddys-laboratories-earns-fda-approval-for-generic/79064#comments</comments>
		<pubDate>Thu, 14 Jul 2011 18:48:53 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[DMF]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[Dreyfus Municipal Income Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RDY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=79064</guid>
		<description><![CDATA[Dr. Reddy’s Laboratories (RDY) delivered yet another positive momentum within a week, as the US Food and Drug Administration (FDA) approved fondaparinux sodium injection, the company’s bioequivalent generic version of Arixtra. The drug is currently marketed by GlaxoSmithKline plc (GSK) for preventing deep vein thrombosis (DVT) in adults who are undergoing hip fracture, hip replacement, or knee replacement surgery. Dr. Reddy’s received final approval from the FDA for the 2.5 mg/ 0.5 mL, 5.0 mg/ 0.4 mL, 7.5 mg/ 0.6 mL and 10 mg/ 0.8 mL doses of fondaparinux sodium injection. Dr. Reddy’s will be manufacturing the generic version under license using a patented process that is developed by Australia based Alchemia Limited. The current approval comes close on the heels of the US launch of the generic version of Novartis ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/14/rdy-dr-reddys-laboratories-earns-fda-approval-for-generic/79064/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SHPGY) Shire Entangled in Legal Dispute</title>
		<link>http://www.stockbloghub.com/2011/07/07/shpgy-shire-entangled-in-legal-dispute/78527</link>
		<comments>http://www.stockbloghub.com/2011/07/07/shpgy-shire-entangled-in-legal-dispute/78527#comments</comments>
		<pubDate>Thu, 07 Jul 2011 16:59:29 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78527</guid>
		<description><![CDATA[The legal tussle between Shire (SHPGY), Sandoz, Inc. &#8212; the generic arm of Novartis (NVS) and Amneal Pharmaceuticals &#8212; intensified with Shire filing a patent infringement case against the two companies relating to Vyvanse. Vyvanse is indicated for treating patients suffering from attention deficit hyperactive disorder (ADHD). Amneal and Sandoz have filed abbreviated new drug applications (ANDAs) with the US Food and Drug Administration (FDA) to market generic versions of Vyvanse at all doses. ADHD refers to a neurobiological disorder that is often hereditary in nature. The disease gives way to lack of attention and often results in impulsiveness and hyperactivity. We note that the marketing exclusivity for Vyvanse expires in February 2012, under the Hatch-Waxman Act. By filing patent infringement lawsuits Shire has ensured a 30-month stay by the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/07/shpgy-shire-entangled-in-legal-dispute/78527/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALXN) Alexion Pharmaceuticals Stands at Neutral</title>
		<link>http://www.stockbloghub.com/2011/07/06/alxn-alexion-pharmaceuticals-stands-at-neutral/78471</link>
		<comments>http://www.stockbloghub.com/2011/07/06/alxn-alexion-pharmaceuticals-stands-at-neutral/78471#comments</comments>
		<pubDate>Wed, 06 Jul 2011 19:32:26 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AHR]]></category>
		<category><![CDATA[Alexion Pharmaceuticals Inc]]></category>
		<category><![CDATA[ALXN]]></category>
		<category><![CDATA[Anthracite Capital Inc.]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78471</guid>
		<description><![CDATA[We are maintaining our Neutral stance on Alexion Pharmaceuticals (ALXN) with a target price of $49.00. Alexion Pharma delivered a strong performance in the first quarter of 2011. First quarter earnings (excluding special items but including stock-based compensation) of 23 cents per share surpassed the Zacks Consensus Estimate by 2 cents and the year-ago earnings by 12 cents. Earnings include the effect of the two-for-one stock split which was completed in May 2011. Earnings in the quarter benefited from an increase in revenues. The main growth driver at Alexion Pharma is Soliris, which is marketed for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare genetic blood disorder. We note that strong Soliris sales have bolstered the company&#8217;s profitability since the second quarter of 2008. Besides PNH, Alexion Pharma is ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/06/alxn-alexion-pharmaceuticals-stands-at-neutral/78471/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(FRX) Forest Laboratories Announces Viibryd Launch</title>
		<link>http://www.stockbloghub.com/2011/07/06/frx-forest-laboratories-announces-viibryd-launch/78478</link>
		<comments>http://www.stockbloghub.com/2011/07/06/frx-forest-laboratories-announces-viibryd-launch/78478#comments</comments>
		<pubDate>Wed, 06 Jul 2011 19:25:54 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78478</guid>
		<description><![CDATA[Forest Laboratories, Inc. (FRX) recently announced the launch of Viibryd (vilazodone HCl) tablets in the US. Viibryd, which is approved for the treatment of adults with major depressive disorder, is available at pharmacies across the US. FDA Approval in Jan 2011 Viibryd received approval from the US Food and Drug Administration (FDA) on Jan 21, 2011. Viibryd became a part of Forest Lab’s portfolio following its acquisition of Clinical Data earlier this year. Besides Viibryd, Forest Labs also gained access to other candidates including phase III candidate, Stedivaze, through this acquisition. Stedivaze is in development as a pharmacologic stress agent for radionuclide myocardial perfusion imaging (MPI). The company expects to launch this product by 2014. We believe Forest Labs is well-positioned for the commercialization of Viibryd given its strong presence ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/06/frx-forest-laboratories-announces-viibryd-launch/78478/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVO) Novo Nordisk Presents Late Stage Degludec Data</title>
		<link>http://www.stockbloghub.com/2011/07/05/nvo-novo-nordisk-presents-late-stage-degludec-data/78249</link>
		<comments>http://www.stockbloghub.com/2011/07/05/nvo-novo-nordisk-presents-late-stage-degludec-data/78249#comments</comments>
		<pubDate>Tue, 05 Jul 2011 14:06:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78249</guid>
		<description><![CDATA[Recently, Novo Nordisk (NVO) presented data from late stage trials, which showed that its ultra-long acting insulin Degludec lowered blood glucose levels with significantly reduced risk of hypoglycemia (low blood sugar) versus Sanofi Aventis’(SNY) Lantus in patients with type II diabetes. Novo Nordisk presented data from two, late stage, 52-week clinical trials, one in patients with type I and the other in victims of type II diabetes. These data were presented at the American Diabetes Association. Degludec particularly reduced nocturnal hypoglycemia (night-time episodes of excessively low blood sugar) versus Lantus in patients with type I or type II diabetes. Nocturnal hypoglycemia is highly feared by diabetics, and hence a reduced threat of it represents a real commercial edge for Degludec. Apart from the two studies, Novo Nordisk also presented data ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/05/nvo-novo-nordisk-presents-late-stage-degludec-data/78249/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ENDP) Endo Pharmaceuticals&#8217; Back Pain Drug Disappoints</title>
		<link>http://www.stockbloghub.com/2011/07/05/endp-endo-pharmaceuticals-back-pain-drug-disappoints/78262</link>
		<comments>http://www.stockbloghub.com/2011/07/05/endp-endo-pharmaceuticals-back-pain-drug-disappoints/78262#comments</comments>
		<pubDate>Tue, 05 Jul 2011 14:04:27 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings Inc]]></category>
		<category><![CDATA[ENDP]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78262</guid>
		<description><![CDATA[Endo Pharmaceuticals (ENDP) recently suffered a pipeline setback with its candidate axomadol performing disappointingly in a mid-stage trial (n=236). Top line results from the study revealed that Endo Pharma’s candidate failed to meet the predetermined end points. The randomized, double blind, two-arm, placebo-controlled study evaluated the candidate in patients suffering from moderate-to-severe chronic low back pain. Endo Pharma in-licensed the US and Canadian development and marketing rights of axomadol from Grunenthal in 2009. The 4-week study evaluated the candidate at doses ranging from 100 mg/day to 300 mg/day. The maintenance phase of the study was 12 weeks. The main goal was a change in the average intensity of pain measured by a numerical rating scale from baseline to the final week of treatment for all patients who were treated with ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/05/endp-endo-pharmaceuticals-back-pain-drug-disappoints/78262/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(FRX) Forest Laboratories Seeks FDA Nod for COPD Drug</title>
		<link>http://www.stockbloghub.com/2011/07/01/frx-forest-laboratories-seeks-fda-nod-for-copd-drug/78228</link>
		<comments>http://www.stockbloghub.com/2011/07/01/frx-forest-laboratories-seeks-fda-nod-for-copd-drug/78228#comments</comments>
		<pubDate>Fri, 01 Jul 2011 20:30:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78228</guid>
		<description><![CDATA[Forest Laboratories, Inc. (FRX) and partner Almirall, S.A. recently announced the submission of a new drug application (NDA) to the US Food and Drug Administration (FDA) for their chronic obstructive pulmonary disease (COPD) candidate, aclidinium bromide. Aclidinium bromide is a long-acting inhaled antimuscarinic agent which has been developed for the treatment of COPD. Top-Line Results Presented in Jan 2011 Forest Labs and Almirall had announced positive top-line data on aclidinium earlier this year. Results were presented from a pivotal phase III study (ATTAIN) that compared the safety and efficacy of aclidinium bromide (200?g and 400?g dosed twice daily) with placebo. Results from the six month double-blind placebo-controlled ATTAIN study, which was conducted in 828 patients with moderate to severe COPD, showed that aclidinium achieved its primary as well as secondary ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/01/frx-forest-laboratories-seeks-fda-nod-for-copd-drug/78228/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WCRX) Warner Chilcott Announces Change in Leadership of Research &amp; Development Division</title>
		<link>http://www.stockbloghub.com/2011/07/01/wcrx-warner-chilcott-announces-change-in-leadership-of-research-development-division/78147</link>
		<comments>http://www.stockbloghub.com/2011/07/01/wcrx-warner-chilcott-announces-change-in-leadership-of-research-development-division/78147#comments</comments>
		<pubDate>Fri, 01 Jul 2011 16:44:24 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[PG]]></category>
		<category><![CDATA[Procter & Gamble Company]]></category>
		<category><![CDATA[Warner Chilcott Limited]]></category>
		<category><![CDATA[WCRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78147</guid>
		<description><![CDATA[Warner Chilcott (WCRX) recently announced that there will be a change at the helm of its research &#38; development (R&#38;D) division from the beginning of next year. The need for change arose following the decision of Warner Chilcott’s incumbent R&#38;D chief, Dr. Fawzi, to resign. Warner Chilcott targets women&#8217;s healthcare, gastroenterology, dermatology and urology markets in the US and Western Europe. Dr. Fawzi is expected to serve the company in his present capacity until the end of 2011. Warner Chilcott has formed a committee to oversee operations of the R&#38;D division until the unit gets a new head. The committee will be headed by Dr. John King, a member of Warner Chilcott’s Board of Directors since 2005. Dr. Fawzi has been with Warner Chilcott since October 2009 when the company ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/01/wcrx-warner-chilcott-announces-change-in-leadership-of-research-development-division/78147/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVO) Novo Nordisk Presents Diabetes Study Data</title>
		<link>http://www.stockbloghub.com/2011/06/29/nvo-novo-nordisk-presents-diabetes-study-data/77767</link>
		<comments>http://www.stockbloghub.com/2011/06/29/nvo-novo-nordisk-presents-diabetes-study-data/77767#comments</comments>
		<pubDate>Wed, 29 Jun 2011 16:42:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77767</guid>
		<description><![CDATA[Recently, Novo Nordisk (NVO) presented data from two extension studies of its lead diabetes drug Victoza at the American Diabetes Association. Victoza is currently marketed as a once-daily human Glucagon-Like Peptide- 1 (GLP-1) analogue for the treatment of type II diabetes. The first study showed that treatment with Victoza (once daily) in combination with metformin and/or sulfonylurea caused more patients to achieve control over their blood sugar levels compared to those treated with other commonly used diabetes drugs like Merck’s (MRK) Januvia and Amylin Pharmaceuticals’ (AMLN) Byetta. Moreover, data also revealed that patients underwent significant weight loss on switching over to Victoza therapy from Januvia. Novo Nordisk also presented data from another late stage study which investigated the effect of adding Levemir to the existing treatment regimen of Victoza and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/29/nvo-novo-nordisk-presents-diabetes-study-data/77767/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SHPGY) Shire to Produce More Replagal</title>
		<link>http://www.stockbloghub.com/2011/06/28/shpgy-shire-to-produce-more-replagal/77664</link>
		<comments>http://www.stockbloghub.com/2011/06/28/shpgy-shire-to-produce-more-replagal/77664#comments</comments>
		<pubDate>Tue, 28 Jun 2011 15:54:31 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[HGT]]></category>
		<category><![CDATA[Hugoton Royalty Trust]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77664</guid>
		<description><![CDATA[UK-based Shire (SHPGY) recently announced that the European Medicines Agency (EMA) has increased the company’s manufacturing flexibility for Replagal (agalsidase alfa), an enzyme replacement therapy approved for treating Fabry disease. The EMA declared that Replagal can be purified at its new manufacturing facility located in Lexington. The European approval for the new manufacturing facility for Replagal was sought by Shire in April 2011. The approval grants Shire, the global market leader for the treatment of Fabry disease, an additional manufacturing facility to purify the product. Prior to the approval, Replagal was purified only at the company’s facility in Alewife, Cambridge. The increased manufacturing strength will enable Shire meet the huge demand for treating the disease in a more efficient manner. Shire’s Replagal competes with Sanofi-Aventis’ (SNY) Fabrazyme in the market ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/28/shpgy-shire-to-produce-more-replagal/77664/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ENDP) Endo Pharmaceuticals Announces FDA Action Date</title>
		<link>http://www.stockbloghub.com/2011/06/27/endp-endo-pharmaceuticals-announces-fda-action-date/77598</link>
		<comments>http://www.stockbloghub.com/2011/06/27/endp-endo-pharmaceuticals-announces-fda-action-date/77598#comments</comments>
		<pubDate>Mon, 27 Jun 2011 18:46:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings Inc]]></category>
		<category><![CDATA[ENDP]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77598</guid>
		<description><![CDATA[Endo Pharmaceuticals (ENDP) recently announced that the US Food and Drug Administration (FDA) has issued a new action date for the new formulation of painkiller Opana ER. The FDA stated that it will review Endo Pharma’s response to the agency’s complete response letter (CRL) by December 13, 2011. The new formulation of Opana ER is designed to resist attempts of crushing, breaking, pulverizing or making a powder of the product. The candidate aims to bring relief to patients suffering from moderate-to-severe pain and in need of continuous opioid treatment for an extended period of time. CRL Issued in January 2011 On January 7, 2011, Endo Pharma announced that the FDA had issued a CRL for the painkiller. Even though the US regulatory body declined to approve the new formulation of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/27/endp-endo-pharmaceuticals-announces-fda-action-date/77598/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SHPGY) Shire&#8217;s Firazyr Earns FDA Panel Backing</title>
		<link>http://www.stockbloghub.com/2011/06/26/shpgy-shires-firazyr-earns-fda-panel-backing/77456</link>
		<comments>http://www.stockbloghub.com/2011/06/26/shpgy-shires-firazyr-earns-fda-panel-backing/77456#comments</comments>
		<pubDate>Sun, 26 Jun 2011 17:48:06 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[EC]]></category>
		<category><![CDATA[Ecopetrol Sa]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77456</guid>
		<description><![CDATA[Recently, the Pulmonary-Allergy Drugs Advisory Committee of the US Food and Drug Administration (FDA) issued a positive opinion and recommended the US approval of Shire’s (SHPGY) Firazyr (icatibant). Shire is looking to get Firazyr approved in the US for treating patients (aged 18 years and above) suffering from acute attacks of hereditary angioedema (HAE). HAE is a rare genetic disease characterized by acute swelling of the hands, feet, face and larynx. The FDA panel was convinced of Firazyr’s safety and effectiveness based on data from three double-blind, randomized late-stage studies (FAST-1, FAST-2, and FAST-3). Twelve of the 13 members of the panel recommended the approval of the drug for the indication. Moreover, 11 of the 13 members (one member voted against the motion while the other panel member abstained from ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/26/shpgy-shires-firazyr-earns-fda-panel-backing/77456/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(RDY) Dr. Reddy’s Laboratories Launches Generic Levaquin</title>
		<link>http://www.stockbloghub.com/2011/06/26/rdy-dr-reddy%e2%80%99s-laboratories-launches-generic-levaquin/77444</link>
		<comments>http://www.stockbloghub.com/2011/06/26/rdy-dr-reddy%e2%80%99s-laboratories-launches-generic-levaquin/77444#comments</comments>
		<pubDate>Sun, 26 Jun 2011 17:46:47 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[DMF]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[Dreyfus Municipal Income Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RDY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77444</guid>
		<description><![CDATA[Dr. Reddy’s Laboratories (RDY) recently announced the launch of its generic version of Johnson &#38; Johnson’s (JNJ) antibiotic drug, Levaquin, in the US. Data from IMS Health reveal that the branded product recorded sales of $1.1 billion in the trailing twelve months ending March 2011. Only recently Dr. Reddy’s announced the launch of three other generic products in the US. The company launched the generic versions of Pfizer Inc.’s (PFE) anti-depressant, Effexor XR, Eisai Co. Ltd.’s Alzheimer’s treatment, Aricept, and Novartis AG’s (NVS) breast cancer treatment, Femara. We believe that the launches of all these generic drugs will bring in additional revenues for Dr. Reddy’s Global Generics segment, which recorded sales of $1.2 billion in fiscal 2011 (ending March 2011), reflecting a sharp year-over-year increase of 10%. Interestingly we note ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/26/rdy-dr-reddy%e2%80%99s-laboratories-launches-generic-levaquin/77444/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VRTX) Vertex Pharmaceuticals Get Positive Data on Incivek</title>
		<link>http://www.stockbloghub.com/2011/06/24/vrtx-vertex-pharmaceuticals-get-positive-data-on-incivek/77386</link>
		<comments>http://www.stockbloghub.com/2011/06/24/vrtx-vertex-pharmaceuticals-get-positive-data-on-incivek/77386#comments</comments>
		<pubDate>Fri, 24 Jun 2011 20:36:58 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[SVR]]></category>
		<category><![CDATA[Syniverse Holdings Inc.]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77386</guid>
		<description><![CDATA[Vertex Pharmaceuticals Inc. (VRTX) recently reported data from two late stage trials – ADVANCE and REALIZE – on Incivek (telaprevir). The data were published in the June edition of the New England Journal of Medicine. The trial results demonstrated that when patients suffering from chronic hepatitis C (HCV) were given Incivek combination therapy, they experienced significant improvement in sustained viral response (SVR) rates, as compared to those who received pegylated-interferon and ribavirin alone. In the ADVANCE study, Incivek combination therapy demonstrated the aforesaid results in new patients, while the REALIZE study consisted of treatment-failed patients. We note that in the ADVANCE study, majority of the patients treated with Incivek combination therapy completed the treatment in 24 weeks, which is half the time needed in the pegylated-interferon and ribavirin arm. Further, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/24/vrtx-vertex-pharmaceuticals-get-positive-data-on-incivek/77386/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ENDP) Endo Pharmaceuticals Holdings Buys American Medical</title>
		<link>http://www.stockbloghub.com/2011/06/22/endp-endo-pharmaceuticals-holdings-buys-american-medical/77023</link>
		<comments>http://www.stockbloghub.com/2011/06/22/endp-endo-pharmaceuticals-holdings-buys-american-medical/77023#comments</comments>
		<pubDate>Wed, 22 Jun 2011 14:55:47 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings Inc]]></category>
		<category><![CDATA[ENDP]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77023</guid>
		<description><![CDATA[Recently, Endo Pharmaceuticals Holdings Inc. (ENDP) completed the purchase of American Medical Systems, a leading pelvic-health device provider, in an all cash deal worth approximately $2.9 billion. By acquiring American Medical, Endo Pharma, a US-based specialty healthcare solutions company that develops branded products and specialty generics, diversified its business and bolstered its urology portfolio. Endo Pharma, while announcing the deal in April 2011, stated that it expected the deal to be accretive to its adjusted earnings with immediate effect following the closure. Endo Pharma had also announced that it expected its 2012 and 2013 adjusted earnings to be boosted by $0.60 and $0.80 per share respectively, as a result of the merger. We note that the purchase of American Medical is the fourth major acquisition for Endo Pharma over the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/22/endp-endo-pharmaceuticals-holdings-buys-american-medical/77023/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(RDY) Dr. Reddy’s Laboratories Announces FDA Warning Letter</title>
		<link>http://www.stockbloghub.com/2011/06/16/rdy-dr-reddy%e2%80%99s-laboratories-announces-fda-warning-letter/76483</link>
		<comments>http://www.stockbloghub.com/2011/06/16/rdy-dr-reddy%e2%80%99s-laboratories-announces-fda-warning-letter/76483#comments</comments>
		<pubDate>Thu, 16 Jun 2011 14:27:31 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[DMF]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[Dreyfus Municipal Income Inc]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RDY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76483</guid>
		<description><![CDATA[Dr. Reddy’s Laboratories (RDY) recently announced that the US Food and Drug Administration (FDA) issued a four item warning letter regarding the company’s chemical manufacturing facility at Cuernavaca, Mexico, which produces Intermediates and Active Pharmaceutical Ingredients. In the four-item warning letter, the FDA has asked for additional data and corrective actions for certain listed items. In order to respond to the warning letter within the stipulated timeframe, Dr. Reddy’s plans to work closely with the regulatory body and resolve the matters contained in the letter. Earlier, in November last year, after inspecting Dr. Reddy’s Mexico facility, the FDA had issued Form FDA 483, with observations. The company responded to the observations by implementing a number of corrective actions. Earlier this week, Dr. Reddy’s announced the launch of three generic products ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/16/rdy-dr-reddy%e2%80%99s-laboratories-announces-fda-warning-letter/76483/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(RDY) Dr. Reddy&#8217;s Laboratories Continues to Grow</title>
		<link>http://www.stockbloghub.com/2011/06/03/rdy-dr-reddys-laboratories-continues-to-grow/74172</link>
		<comments>http://www.stockbloghub.com/2011/06/03/rdy-dr-reddys-laboratories-continues-to-grow/74172#comments</comments>
		<pubDate>Fri, 03 Jun 2011 14:11:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ADS]]></category>
		<category><![CDATA[Alliance Data Systems Corporation]]></category>
		<category><![CDATA[DMF]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[Dreyfus Municipal Income Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[Valeant Pharmaceuticals International]]></category>
		<category><![CDATA[VRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=74172</guid>
		<description><![CDATA[Dr. Reddy’s Laboratories (RDY) reported fiscal 2011 earnings per American Depositary Share (ADS) of $1.50 compared with 10 cents per ADS posted in fiscal 2010. Higher revenues and lower operating expenses helped boost earnings. Year at a Glance The company reported revenues of $1.7 billion during the fiscal year, reflecting a year-over-year increase of 6%. Dr. Reddy’s reports revenues under two segments – Global Generics and Pharmaceutical Services &#38; Active Ingredients (PSAI). Revenues at the Global Generics segment increased 10% to $1.2 billion. However, PSAI revenues declined 4% to $441 million during the year. While generics revenues increased 18% in North America, 19% in Russia and other CIS (Commonwealth of Independent States) markets, and 15% in India, they deteriorated 13% in Europe. In the European market, Germany was worst hit ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/03/rdy-dr-reddys-laboratories-continues-to-grow/74172/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ENDP) Endo Pharmaceuticals Evenly Poised</title>
		<link>http://www.stockbloghub.com/2011/05/30/endp-endo-pharmaceuticals-evenly-poised/74362</link>
		<comments>http://www.stockbloghub.com/2011/05/30/endp-endo-pharmaceuticals-evenly-poised/74362#comments</comments>
		<pubDate>Mon, 30 May 2011 15:24:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[American Medical Systems Holdings Inc]]></category>
		<category><![CDATA[AMMD]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings Inc]]></category>
		<category><![CDATA[ENDP]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=74362</guid>
		<description><![CDATA[We are maintaining our Neutral stance on Endo Pharmaceuticals (ENDP) with a target price of $44.00. Headquartered in Chadds Ford, Pennsylvania and founded in 1997, Endo Pharma is a specialty healthcare solutions company. The company, which operates in the US, reports results through three segments: Branded Pharmaceuticals, Generics and Devices and Services. Endo Pharma offers more than 175 products in the areas of pain management, urology and oncology. In April 2011, Endo Pharma reported its first quarter 2011 results. First quarter adjusted earnings of $1.00 per share were in line with the Zacks Consensus Estimate but $0.26 above the year ago figure. The year-over-year rise in earnings was attributable to the higher revenues reported in the first quarter of 2011. We note that Endo Pharma is on an acquisition spree ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/30/endp-endo-pharmaceuticals-evenly-poised/74362/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDCO) The Medicines Company Analyst Reiterates Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2011/05/27/mdco-the-medicines-company-analyst-reiterates-neutral-on-shares/75058</link>
		<comments>http://www.stockbloghub.com/2011/05/27/mdco-the-medicines-company-analyst-reiterates-neutral-on-shares/75058#comments</comments>
		<pubDate>Fri, 27 May 2011 13:41:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PowerShares Autonomic Gr NFA Gbl Asset]]></category>
		<category><![CDATA[PTO]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=75058</guid>
		<description><![CDATA[We recently reiterated a Neutral recommendation on The Medicines Company (MDCO), which carries a Zacks #3 Rank (short-term Hold rating). The Medicines Company reported a first-quarter profit of 60 cents per share, well above the Zacks Consensus Estimate of 39 cents and the year-ago profit of 19 cents. Performance was boosted by higher revenues. Revenues, up 9.8% at $112.1 million, surpassed the Zacks Consensus Estimate of $110 million. The Medicines Company’s lead product, Angiomax (bivalirudin), is a specific and reversible direct thrombin inhibitor that was launched in early 2001. Despite the challenging economic scenario which has led to hospitals and patients cutting down on costly procedures, Angiomax sales in the first quarter of 2011 were up 9.7% year over year in the US. The Medicines Company received a major boost ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/27/mdco-the-medicines-company-analyst-reiterates-neutral-on-shares/75058/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VRX) Valeant Pharmaceuticals Beats Earnings Estimates on Revenues</title>
		<link>http://www.stockbloghub.com/2011/05/18/vrx-valeant-pharmaceuticals-beats-earnings-estimates-on-revenues/73944</link>
		<comments>http://www.stockbloghub.com/2011/05/18/vrx-valeant-pharmaceuticals-beats-earnings-estimates-on-revenues/73944#comments</comments>
		<pubDate>Wed, 18 May 2011 15:22:13 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Valeant Pharmaceuticals International]]></category>
		<category><![CDATA[VRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73944</guid>
		<description><![CDATA[Valeant Pharmaceuticals International‘s (VRX) first quarter 2011 earnings of 49 cents per share (excluding special items but including stock-based compensation expense) missed the Zacks Consensus Estimate by 2 cents and the year-ago earnings by 10 cents per share. Revenues for the quarter increased to $565 million, well above the Zacks Consensus Estimate of $517 million and the prior-year quarter’s revenue of $219.6 million. However, revenue included a one-time alliance and royalty revenue of $36 million related to the March 2011 out-licensing of product rights to Cloderm cream, a mid-potency steroid to Dr. Reddy&#8217;s Laboratories (RDY). Excluding the one-time payment, revenue was $529 million, which was still above both the Zacks Consensus Estimate and the prior-year revenue. Organically (excluding the impact of one-time revenues, acquisitions and foreign exchange), revenues grew 7% ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/18/vrx-valeant-pharmaceuticals-beats-earnings-estimates-on-revenues/73944/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ISIS) Isis Pharmaceuticals Reported Loss Widens</title>
		<link>http://www.stockbloghub.com/2011/05/09/isis-isis-pharmaceuticals-reported-loss-widens/73669</link>
		<comments>http://www.stockbloghub.com/2011/05/09/isis-isis-pharmaceuticals-reported-loss-widens/73669#comments</comments>
		<pubDate>Mon, 09 May 2011 21:33:40 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[OGXI]]></category>
		<category><![CDATA[OncoGenex Pharmaceuticals Inc]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73669</guid>
		<description><![CDATA[Isis Pharmaceuticals Inc. (ISIS) reported a net loss of 20 cents per share in the first quarter of 2011, wider than the year-ago loss of 10 cents and the Zacks Consensus loss Estimate of 19 cents. Revenues came in at $21.1 million, well below the Zacks Consensus Estimate of $26 million. Lower revenues and higher operating expenses led to the wider first quarter 2011 loss. Quarter in Detail Revenues, which include license fees, milestone-related payments and other payments, declined 29.3% from the year-ago period during the first quarter of 2011. Isis Pharma earned a $750,000 milestone payment from OncoGenex (OGXI) on the initiation of a phase II study with OGX-427. First quarter revenues also included revenues recognized under the company’s collaboration agreement with GlaxoSmithKline (GSK). Isis Pharma could receive another ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/09/isis-isis-pharmaceuticals-reported-loss-widens/73669/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VRTX) Vertex Pharmaceuticals Posts Wider Loss</title>
		<link>http://www.stockbloghub.com/2011/05/08/vrtx-vertex-pharmaceuticals-posts-wider-loss-2/73436</link>
		<comments>http://www.stockbloghub.com/2011/05/08/vrtx-vertex-pharmaceuticals-posts-wider-loss-2/73436#comments</comments>
		<pubDate>Sun, 08 May 2011 15:51:46 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MAA]]></category>
		<category><![CDATA[Mid-America Apartment Communities Inc]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73436</guid>
		<description><![CDATA[Vertex Pharmaceuticals Inc. (VRTX) posted first-quarter 2011 loss (including stock-based compensation expense) of $1.05 per share, in line with the Zacks Consensus Estimate, but wider than the year-ago loss of 80 cents. Increased expenses related to the potential launch of hepatitis C virus (HCV) candidate, Incivek (proposed US trade name for telaprevir), led to the higher loss. Revenues Revenues for the reported quarter increased 229% to $73.7 million, exceeding the Zacks Consensus Estimate of $25 million. First quarter revenues included a $50 million milestone payment received from Johnson &#38; Johnson (JNJ), on the acceptance of the Marketing Authorization Application (MAA) for Incivek in Europe. Vertex Pharma’s first quarter revenues consisted of royalty revenues (down 5.4% to $6.1 million) and collaborative revenues (up 321.9% to $67.6 million). The company receives royalty ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/08/vrtx-vertex-pharmaceuticals-posts-wider-loss-2/73436/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CEPH) Cephalon First Quarter 2011 Earnings Miss Expectations</title>
		<link>http://www.stockbloghub.com/2011/05/05/ceph-cephalon-first-quarter-2011-earnings-miss-expectations/73295</link>
		<comments>http://www.stockbloghub.com/2011/05/05/ceph-cephalon-first-quarter-2011-earnings-miss-expectations/73295#comments</comments>
		<pubDate>Thu, 05 May 2011 15:46:59 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Valeant Pharmaceuticals International]]></category>
		<category><![CDATA[VRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73295</guid>
		<description><![CDATA[Cephalon Inc. (CEPH) delivered first quarter earnings of $1.98 per share, several cents below the Zacks Consensus Estimate of $2.04 but 12.5% above the year-ago earnings of $1.76. First quarter revenues, which increased 24.9% to $745.1 million, missed the Zacks Consensus Estimate of $752 million by a wide margin. First quarter results were within the guidance range provided by the company. Cephalon had guided towards adjusted net income of $144 &#8211; $159 million on sales of $725 &#8211; $755 million. The Quarter in Detail First quarter revenues consisted of $736 million in product sales (up 27.6%) and $9.1 million in other revenues. All segments performed well during the quarter. The central nervous system (CNS) and oncology franchises posted sales of $334.7 million (up 7%) and $149.1 million (up 35%), respectively. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/05/ceph-cephalon-first-quarter-2011-earnings-miss-expectations/73295/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AGN) Company News for May 5, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/05/05/agn-company-news-for-may-5-2011-corporate-summary/73364</link>
		<comments>http://www.stockbloghub.com/2011/05/05/agn-company-news-for-may-5-2011-corporate-summary/73364#comments</comments>
		<pubDate>Thu, 05 May 2011 13:56:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[AMAT]]></category>
		<category><![CDATA[Applied Materials Inc.]]></category>
		<category><![CDATA[CAG]]></category>
		<category><![CDATA[CBS]]></category>
		<category><![CDATA[CBS Corporation]]></category>
		<category><![CDATA[ConAgra Foods Inc.]]></category>
		<category><![CDATA[Novellus Systems Inc.]]></category>
		<category><![CDATA[NVLS]]></category>
		<category><![CDATA[PRU]]></category>
		<category><![CDATA[Prudential Financial Inc.]]></category>
		<category><![CDATA[R.R. Donnelley & Sons Company]]></category>
		<category><![CDATA[RAH]]></category>
		<category><![CDATA[Ralcorp Holdings Inc.]]></category>
		<category><![CDATA[RRD]]></category>
		<category><![CDATA[Varian Semiconductor Equipment Associates Inc]]></category>
		<category><![CDATA[VSEA]]></category>
		<category><![CDATA[Williams Companies Inc.]]></category>
		<category><![CDATA[WMB]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73364</guid>
		<description><![CDATA[•    R.R. Donnelley &#38; Sons (NYSE:RRD) reported Q1 EPS of $0.33, missing the Zacks Consensus Estimate of $0.36 per share. Revenues for the quarter rose 7% year-over-year to $2.58 billion, lower than the Zacks Consensus Estimate of $2.634 billion •    The Williams Companies (NYSE:WMB) reported Q1 EPS of $0.36 ex-items today, slightly higher than the Zacks Consensus estimate of $0.35 per share •    Prudential Financial (NYSE:PRU) reported Q1 earnings per common share of $1.69 ex-items, beating the Zacks Consensus Estimate for $1.48 per share. Revenues for the quarter grew 28% year-over-year to $9.20 billion, above the Zacks Consensus Estimate of $8.196 billion •    CBS Corporation (NYSE:CBS) increased 7.19% to close the day at $27.21 after the company doubled its dividend and reported first- quarter profits that beat analysts’ estimates •    ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/05/agn-company-news-for-may-5-2011-corporate-summary/73364/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GERN) Geron 2011 First Quarter Posts Wider Loss</title>
		<link>http://www.stockbloghub.com/2011/05/03/gern-geron-2011-first-quarter-posts-wider-loss/72990</link>
		<comments>http://www.stockbloghub.com/2011/05/03/gern-geron-2011-first-quarter-posts-wider-loss/72990#comments</comments>
		<pubDate>Tue, 03 May 2011 18:33:29 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GERN]]></category>
		<category><![CDATA[Geron Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=72990</guid>
		<description><![CDATA[Geron Corporation (GERN) posted a net loss of 20 cents per share in the first quarter of 2011, wider than the Zacks Consensus Estimate of a loss of 19 cents and the year-ago loss of 18 cents. First quarter revenues of $1.5 million were just above the Zacks Consensus Estimate of $1 million and higher than the year-ago revenues of $0.9 million. Higher expenses led to the wider first quarter loss. Quarter in Detail Revenues consisted of $150,000 in revenues from collaborative agreements and $1.4 million in the form of royalties and license fees. Geron has several license agreements with various oncology, diagnostics, research tools, agriculture and biologics production companies. Total operating expenses were $25.9 million, 48.7% above the $17.4 million reported in the year-ago period. Research and development expenses ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/03/gern-geron-2011-first-quarter-posts-wider-loss/72990/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TEVA) Teva Pharmaceutical Industries Announces Aquisition of Cephalon</title>
		<link>http://www.stockbloghub.com/2011/05/03/teva-teva-pharmaceutical-industries-announces-aquisition-of-cephalon/73024</link>
		<comments>http://www.stockbloghub.com/2011/05/03/teva-teva-pharmaceutical-industries-announces-aquisition-of-cephalon/73024#comments</comments>
		<pubDate>Tue, 03 May 2011 18:10:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Valeant Pharmaceuticals International]]></category>
		<category><![CDATA[VRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73024</guid>
		<description><![CDATA[Yet another acquisition deal was announced in the pharma sector with generic player, Teva Pharmaceutical Industries Ltd. (TEVA) entering into a definitive agreement with Cephalon, Inc. (CEPH). Teva intends to acquire Cephalon for $81.50 per share in cash or $6.8 billion. Teva Tops Valeant Bid Cephalon has been in the news over the past few weeks with Valeant Pharmaceuticals (VRX) expressing an interest in acquiring the company. Valeant had initially approached Cephalon in late March with a $73 bid. However, Cephalon rejected the offer. Teva’s offer price tops Valeant’s offer and represents a 39% premium to Cephalon’s stock price before Valeant’s unsolicited proposal was announced. Deal in line with Long-Term Strategy The Cephalon deal is in line with Teva’s long-term strategy of expanding and strengthening its branded and specialty pharma ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/03/teva-teva-pharmaceutical-industries-announces-aquisition-of-cephalon/73024/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

